Reumatología Clínica Reumatología Clínica
Reumatol Clin 2006;2:190-201 - Vol. 2 Núm.4 DOI: 10.1016/S1699-258X(06)73045-5
Revisiones
Antipalúdicos: actualización de su uso en enfermedades reumáticas
Antimalarials: an update in rheumatic diseases
Mercedes Jiménez Palop??,
Servicio de Reumatología. Hospital Universitario Puerta de Hierro. Madrid. España
Recibido 29 junio 2005, Aceptado 04 octubre 2005
Resumen

Los antipalúdicos son antiguos fármacos utilizados desde el siglo XIX para el tratamiento de las manifestaciones cutáneas del lupus y de la artritis reumatoide. En las últimas décadas, estos fármacos han consolidado su uso en dichas enfermedades y han incorporado nuevos mecanismos de acción, ampliando sus perspectivas terapéuticas. Son el tratamiento de elección en las manifestaciones leves y moderadas del lupus eritematoso sistémico y se han asentado como terapia combinada en la artritis reumatoide. Han mostrado sus efectos beneficiosos sobre la aterosclerosis, así como un possible papel en el tratamiento precoz del síndrome antifosfolipídico. Finalmente, muestran una potencial utilidad en otras enfermedades reumáticas como el síndrome de Sjögren y el reumatismo palindrómico. Esta revisión trata de realizar una puesta al día del uso de estos fármacos en reumatología, así como del control de su toxicidad.

Resumen

Antimalarials are long-standing drugs that have been used since the nineteenth century for the treatment of skin rashes and lesions in lupus and rheumatoid arthritis. In recent decades, their use in these disorders has been consolidated, and new mechanisms of action have been incorporated, broadening the therapeutic perspectives of these drugs. Antimalarials are the treatment of choice in mild and moderate manifestations of systemic lupus erythematosus and are established as part of combined therapy in rheumatoid arthritis. They have been shown to have beneficial effects on atherosclerosis, as well as a possible role in the early treatment of antiphospholipid syndrome. Lastly, they have been shown to have a potential use in other rheumatic diseases such as Sjögren’s Syndrome and palindromic rheumatism. This review aims to provide an update on the use of these drugs in rheumatology and to discuss their toxicity profile.

Palabras clave
Antipalúdicos, Cloroquina, Hidroxicloroquina, Lupus eritematoso sistémico, Artritis reumatoide
Key words
Antimalarials, Chloroquine, Hydroxychloroquine, Systemic lupus erythematosus, Rheumatoid arthritis
El Texto completo solo está disponible en PDF
Bibliografía
1.
F. Page
Treatment of lupus erythematosus with mepacrine
Lancet, 2 (1951), pp. 755-758
2.
D.J. Wallace
The History of antimalarial
Lupus, 5 (1996), pp. S2-S3
3.
D.J. Wallace
Is there a role for quinacrina (Atabrine) in the new millennium
Lupus, 9 (2000), pp. 81-82
4.
E. Toubi,I. Rosner,M. Rozenbaum,A. Kessel,T.D. Golan
The benefit ofcombining hydroxychloroquine with quinacrine in the treatment of SLE patients
Lupus, 9 (2000), pp. 92-95
5.
A.L. Scherbel,J.W. Harrison,M. Atdjan
Further observations on the use of 4-aminoquinoline compounds in patients with rheumatoid arthritis related diseases
Cleve Clin Q, 25 (1958), pp. 95
6.
D.E. Furst
Pharmacokinetics of hydroxychloroquine and chloroquine during treatment of rheumatic diseases
Lupus, 5 (1996), pp. S11-S15
7.
T. Munster,J.P. Gibbs,D. Shen,B.A. Baethge,G.R. Botstein,J. Caldwell
Hydroxychloroquine concentration-response relationships in patients with rheumatoid arthritis
Arthritis Rheum, 46 (2002), pp. 1460-1469 http://dx.doi.org/10.1002/art.10307
8.
R.B. Landewe,M.S. Vergouwen,S.G. Goeei The,A.W. Van Rijthoven,F.C. Breedveld,B.A. Dijkmans
Antimalarial drug induced decrease in creatinine clearance
J Rheumatol, 22 (1995), pp. 34-37
9.
M. Rubin,H.N. Bernstein,N.J. Zvaifler
Studies on the pharmacology of chloroquine
Arch Ophthalmol, 70 (1962), pp. 474
10.
J. Aponte,M. Petrelli,N. Von Dawson
Liver enzyme levels in artritis patirnts treated with long-term bolus methotrexate
Arthritis Rheum, 35 (1992), pp. 126-128
11.
M.L. Jewell,D.P. McCauliffe
Patients with cutaneous lupus erythematosus who smoke are less responsive to antimalarial treatment
J Am Acad Dermatol, 42 (2000), pp. 983-987
12.
B. Pool,S. Ohkuma
Effect of weak bases on the intralysosomal pH in mouse peritoneal macrophages
J Cell Biol, 90 (1981), pp. 665-669
13.
R.I. Fox
Mechanism of action of hydroxychloroquine as an antirheumatic drug
Sem Arthritis Rheum, 23 (1993), pp. 82-91
14.
R. Fox
Anti-malarial drugs: possible mechanisms of action in autoimmune disease and prospects for drugs development
Lupus, 5 (1996), pp. S4-S10
15.
R.I. Rynes
Antimalarial drugs in the treatment of rheumatological diseases
J Rheumatol, 36 (1997), pp. 799-805
16.
J. Bondeson,R. Sundler
Antimalarial drugs inhibit phospholipase A2 activation and induction of interleuk in 1β and tumor necrosis factor a inmacrophages: implications for their mode of action in rheumatoid arthritis
Gen Pharmac, 30 (1998), pp. 357-366
17.
G.M. Murphy,J.L.M. Hawk,I.A. Magnus
Hydroxychloroquine in polymorphic light eruption: a controlled trial with drug and visual sensitivity monitoring
Brit J Dermatol, 116 (1987), pp. 379-386
18.
A. Wozniacka,A. Carter,D.P. McCauliffe
Antimalarials in cutaneous lupus erythematosus: mechanisms of therapeutic benefit
Lupus, 11 (2000), pp. 71-81
19.
T.Q. Nguyen,J.D. Capra,R.D. Sontheimer
4-aminoquinoline antimalarials enhance UV-B induced c-jun transcriptional activation
Lupus, 7 (1998), pp. 148-153
20.
H. Lafont,F. Chanussor,C. Dupuy,P. Lechene,D. Lairon,M. Charbonnier-Augeire
Influence of acute injection of chloroquine on the biliary secretion of lipids and lysosomal enzyme on rats
Lipids, 19 (1984), pp. 195-201
21.
J.L. Goldstein,G.Y. Brunschede,M.S. Brown
Inhibition of ptoteolytic degradation of low density lipoprotein in human fibroblasts by chloroquine, concanavalin A and Triton WR 1339
J Biol Chem, 250 (1975), pp. 7854-7862
22.
H.W. Chen,D.A. Leonard
Chloroquine inhibits cyclization of squaleneoxide to lanosterol in mammalians cells
J Biol Chem, 259 (1984), pp. 8156-8162
23.
A.C. Beynen,A.J. Van der Moolen,M.J.H. Geelen
Inhibition of hepaticcolesterol síntesis by chloroquine
Lipids, 16 (1981), pp. 472-474
24.
K.L.G. Svenson,H. Lithell,R. Hällgren,B. Vessby
Serum lipoprotein inactive rheumatoid arthritis and other chronic inflammatory arthritides. II. Effects of anti-inflammatory and disease-modifying drug treatment
Arch Intern Med, 147 (1987), pp. 1917-1920
25.
D.J. Wallace,A.L. Metzger,V.J. Stecher,B.A. Turnbull,P.A. Kern
Cholesterol-lowering effect of hydroxychloroquine in patients with rheumatic disease: reversal of deleterious effects of steroids on lipids
Am J Med, 89 (1990), pp. 322-326
26.
L.S. Tam,E.K. Li,C.W. Lam,B. Tomlinson
Hydroxychloroquine has nosignificant effect on lipids and apolipo proteins in Chinese systemic lupus erythematosus patients with mild or inactive disease
Lupus, 9 (2000), pp. 413-416
27.
H.N. Hodis,F.P. Quismorio,E. Wickham,D.H. Blankenhorn
The lipid, lipoprotein, and apolipoprotein effects of hydroxychloroquine in patients with systemic lupus erythematosus
J Rheumatol, 20 (1993), pp. 661-665
28.
M. Petri,C. Lakata,L. Magder,D. Goldman
Effect of prednisone and hydroxychloroquine on coronary artery disease risk factors in systemic lupuserythematosus: a longitudinal data análisis
Am J Med, 96 (1994), pp. 254-259
29.
A. Kavanaugh,B. Adams-Huet,R. Jain,M. Denke,J. McFarlin
Hydroxychloroquine effects on lipoprotein profiles (the HELP trial): a double-blind, randomized, placebo-controlled, pilot study in patients with systemic lupus erythematosus
J Clin Rheumatol, 3 (1997), pp. 3-8
30.
R. Munro,E. Morrison,A.G. McDonald,J.A. Hunter,R. Madhok,H.A. Capell
Effect of disease modifying agents on the lipid profiles of patients with rheumatoid arthritis
Ann Rheum Dis, 56 (1997), pp. 374-377
31.
P. Rahman,D.D. Gladman,M.B. Urowitz,K. Yuen,D. Hallett,I.N. Bruce
The cholesterol lowering effect of antimal arial drugs is enhanced in patients with lupus taking corticosteroid drugs
J Rheumatol, 26 (1999), pp. 325-330
32.
L.S. Tam,D.D. Gladman,D.C. Hallett,P. Rahman,M.B. Urowitz
Effect ofantimal arial agents on the fasting lipid profile in systemic lupus erythematosus
Rheumatol, 27 (2000), pp. 2142-2145
33.
E.F. Borba,E. Bonfá
Longterm beneficial effect of choloroquine diphosphateon lipoprotein profile in lupus patients with and without steroidtherapy
J Rheumatol, 28 (2001), pp. 780-785
34.
R.E. Phillips,S. Looareesuwan,N.J. White,P. Chanthavanich,J. Karbwang,W. Supanaranond
Hypoglycemia and antimal arial drugs: quinidine and release of insulin
BMJ, 292 (1986), pp. 1319-1321
35.
A. Quatraro,G. Consoli,M. Magno,F. Caretta,A. Nardozza,A. Ceriello
Hydroxychloroquine in decompensated treatment-refractory noninsulin- dependent diabetes mellitus. A new job for an old drug?
Ann Intern Med, 112 (1990), pp. 678-681
36.
M. Petri
Hydroxychloroquine use in the Baltimore lupus cohort: effects on lipids, glucose and thrombosis
Lupus, 5 (1996), pp. S16-S22
37.
K. Shojania,B.E. Koehler,T. Elliott
Hypoglycemia induced by hydroxychloroquinein a type II diabetic treated for polyarthritis
J Rheumatol, 26 (1999), pp. 195-196
38.
J.R. Loudon
Hydroxychloroquine and postoperative thromboembolism after total hip replacement
Am J Med, 85 (1988), pp. 57-61
39.
A.E. Carter,R. Eban,R.D. Perrett
Prevention of post-operative deep venous thrombosis and pulmonary embolism
BMJ, 1 (1971), pp. 312-314
40.
A.E. Carter,R. Eban
Prevention of postoperative deep venous trombosis in legs by orally administered hydroxychloroquine sulfate
BMJ, 3 (1974), pp. 94-95
41.
D.B. Pilcher
Hydroxychloroquine sulfate in prevention of thromboembolic phenomena in surgical patients
Am Surgeon, 41 (1975), pp. 761-766
42.
E.H. Hansen,P. Jessing,H. Lindewald,P. Ostergaard,T. Olesen,E.I. Malver
Hydroxychloroquine sulphate in prevention of deep venous thrombosis following of the hip, pelvis, or thoracolumbar spine
J Bone Joint Surg Am, 58 (1976), pp. 1089-1093
43.
D.O. Chrisman,G.A. Snook,T.C. Wilson,J.Y. Short
Prevention of venous thromboembolism by administration of hydroxychloroquine
J Bone Joint Surg Am, 58 (1976), pp. 918-920
44.
E.D. Cook,M.H. Dawson,R.M. Ibbotson,S.A. Bowcock,M.E. Ainsworth,M.F. Pilcher
Failure of orally administered hydroxychloroquine sulphate to prevent venous thromboembolism following elective hip operations
J Bone Joint Surg Am, 59 (1977), pp. 496-500
45.
T.K. Wu,M.J. Tsapogas,F.R. Jordan
Prophylaxis of deep venous trombosis by hydroxychloroquine sulfate and heparin
Surg Gynecol Obstet, 145 (1977), pp. 714-718
46.
E. Johansson,K. Forsberg,H. Johnsson
Clinical and experimental evaluation of the thromboprophylactic effect of hydroxychloroquine sulfate after total hip replacement
Haemostasis, 10 (1981), pp. 89-96
47.
E. Bertrand,B. Cloitre,R. Ticolat,R.K. Bile,C. Gautier,G.O. Abiyou
Antiaggregation action of cholroquine
Med Trop, 50 (1990), pp. 143-146
48.
R. Nosal,V. Jancinova,M. Petrikova
Chloroquine inhibits atimulatedplatelets at the arachidonic acid pathway
49.
B.P. Madow
Use of antimalarial drugs as “desludging” agents in vascular disease processes
JAMA, 172 (1960), pp. 1630-1633
50.
M.H. Edwards,S. Pierangeli,X.W. Liu,J.H. Barker,G. Anderson,E.N. Harris
Hydroxychloroquine reverses thrombogenic properties of antiphospholipid antibodies in mice
Circulation, 96 (1997), pp. 4380-4384
51.
D.J. Wallace
Does hydroxychloroquine sulfate prevent clot formation in systemic lupus erythematosus?
Arthritis Rheum, 30 (1987), pp. 1435-1436
52.
D.J. Wallace,M. Linker-Israeli,A.L. Metzger,V.J. Stecher
The relevance of antimalarial theraphy with regard to thrombosis, hypercholesterolemia and cytokines in SLE
Lupus, 2 (1993), pp. S13-S15
53.
M. Petri,Hochberg,D. Hellmann,D. Goldman
Incidence and predictorsof thrombotic events in SLE: protective role of hydroxychloroquine
Arthritis Rheum, 35 (1992), pp. S54
54.
G.A. McCarthy
Hydroxychloroquine (HCQ) treatment in antiphospholipid antibody syndrome (APS): time course of clinical improvement and antiphospholipid antibody (aPL) titer changes over 4 years
Arthiritis Rheum, 43 (2000), pp. S1061
55.
Khamashta MA, Wallace DJ, editors. Antimalarial in rheumatology. Lupus. 1996;5 Suppl 1:S1-73.
56.
K.H. Yoon
Sufficient evidence to consider hydroxychloroquine as an adjunct therapy in Antiphospholipid Antibody (Hughes’) Syndrome
J Rheumatol, 29 (2002), pp. 1574
57.
D.J. Wallace
Antimalarial agents and lupus
Rheum Dis Clin N Am, 20 (1994), pp. 243-263
58.
J.V. Christiansen,J.P. Nielsen
Treatment of lupus erytematosus with mepacrine: results and relapses during a long observation
Brit J Dermatol, 68 (1956), pp. 73-87
59.
M. Ziff,P. Esserman,C. McEwen
Observations on the course and treatment of systemic lupus erythematosus
Arthritis Rheum, 1 (1958), pp. 332-350
60.
E.L. Dubois,S. Martel
Discoid lupus erythematosus; an analysis of its systemic manifestations
Ann Intern Med, 44 (1956), pp. 482-496
61.
R.D. Rudnicki,G.E. Gresham,N.F. Rothfield
The efficacy of antimalarialsin systemic lupus erythematosus
J Rheumatol, 2 (1975), pp. 323-330
62.
The Canadian Hydroxychloroquine Study Group
A randomized studyof of the effect of withdrawing hydroxychloroquine sulfate in systemic lupus erythematosus
New Engl J Med, 324 (1991), pp. 150-154 http://dx.doi.org/10.1056/NEJM199101173240303
63.
E. Tsakonas,L. Joseph,J.M. Esdaile,D. Choquette,J.L. Senecal,A. Cividino
A long-term study of hydroxychloroquine withdrawal on exacerbations in systemic lupus erythematosus
Lupus, 7 (1998), pp. 80-85
64.
H.J. Williams,M.J. Egger,J.Z. Singer,R.F. Willkens,K.C. Kalunian,D.O. Clegg
Comparison of hydroxychloroquine and placebo in the treatment of the arthropathy of mild systemic lupus erythrmatosus
J Rheumatol, 21 (1994), pp. 1457-1462
65.
I.M. Meinao,E.I. Sato,L.E. Andrade,M.B. Ferraz,E. Atra
Controlled trial with chloroquine diphosphate in systemic lupus erythematosus
Lupus, 5 (1996), pp. 237-241
66.
E.F. Morand,P.I. McCloud,G.O. Littlejohn
Continuation of long term treatment with hydroxychloroquine in systemic lupus erythematosus and rheumatoid arthritis
Ann Rheum Dis, 51 (1992), pp. 1318-1321
67.
M. Petri
Hydroxychloroquine: past, present, future
Lupus, 7 (1998), pp. 65-67
68.
Y. Molad,A. Gorshtein,A.J. Wysenbeek,D. Guedj,R. Majadla,A. Weinberger
Protective effect of hydroxychloroquine in systemic lupus erythematosus. Prospective long-term study of Israeli cohort
Lupus, 11 (2002), pp. 356-361
69.
B.J. Fessler,G.S. Alarcón,G. McGwin,J. Roseman,H.M. Bastian,A.W. Friedman
Systemic lupus erythematosus in three ethnic groups: XVI. Association of hydroxychloroquine use with reduced risk of damage accrual
Arthritis Rheum, 52 (2005), pp. 1473-1480 http://dx.doi.org/10.1002/art.21039
70.
S. Jessop,D. Whitelaw,F. Jordaan
Drugs for lupus erythematosus (Cochrane Review)
The Cochrane Library, Issue 2, John Wiley & Sons, Ltd., (2004)
71.
B.H. Hahn
Systemic lupus erythematosus and accelerated atherosclerosis
N Engl J Med, 349 (2003), pp. 2379-2380 http://dx.doi.org/10.1056/NEJMp038168
72.
M.J. Davis,A.D. Woolf
Role of antimalarial in rheumatoid arthritis –the Brithish experience
Lupus, 5 (1996), pp. S37-S40
73.
M.M. Khraishi,G. Singh
The role of anti-malarial in rheumatoid arthritis– the American experience
Lupus, 5 (1996), pp. S41-S44
74.
M.B. Suárez-Almanzor,E. Belseck,B. Shea,J. Holmik,G. Wells,P. Tugwell
Drogas antipalúdicas para la artritis reumatoidea
La CochraneLibrary plus en español, Update Software, (2000)
75.
W.D. Blackburn,H.M. Prupas,J.C. Silverfield,J.E. Poiley,J.R. Caldwell,R.L. Collins
Tenidap in rheumatoid arthritis. A 24-week double-bindcomparison with hydroxychloroquine-plus-piroxicam and piroxicam alone
Arthritis Rheum, 38 (1995), pp. 1447-1456
76.
P. Clark,E. Casas,P. Tugwell,C. Medina,C. Gheno,G. Tenorio
Hydroxy chloroquine compared with placebo in rheumatoid arthritis. A randomized controlled trial
Ann Intern Med, 119 (1993), pp. 1067-1071
77.
M.J. Davis,P.T. Dawes,P.D. Fowler,S. Clarke,J. Fisher,M.F. Shadforth
Should disease-modifying agents be used in mild rheumatoid arthritis
J Rheumatol, 30 (1991), pp. 451-454
78.
J.M. Esdaile,S. Suissa,J.B. Shiroky,D. Lamping,E. Tsakonas,D. Anderson
A randomized trial of hydroxychloroquine in early rheumatoidarthritis: the HERA study
Am J Med, 98 (1995), pp. 156-168
79.
D.T. Felson,J.J. Anderson,R.F. Meenan
Use of short-term efficacy/toxicitytradeoffs to select second-line drugs in rheumatoid arthritis: a metaanalysis of published clinicals trials
Arthritis Rheum, 35 (1992), pp. 1117-1125
80.
M. Csuka,G.F. Carrera,D.J. McCarty
Treatment of intractable rheumatoid arthritis with combined cyclophosphamide, azathioprine, and hydroxychloroquine. A follow-up study
JAMA, 255 (1986), pp. 2315-2319
81.
N.A. Tialakos
Low-dose cytotoxic drug combianation therapy in intractablerheumatoid artritis: two years later
Arthritis Rheum, 29 (1986), pp. S79
82.
D.J. McCarty,J.G. Harman,J.L. Grassanovich,C. Oian,J.P. Klein
Combinationdrug therapy of seropositive rheumatoid arthritis
J Rheumatol, 22 (1995), pp. 1636-1645
83.
W.S. Wilke,J.D. Clough
Therapy for rheumatoid arthritis: combinationsof disease-modifying drugs and new paradigms of treatment
Semin Arthritis Rheum, 21 (1991), pp. 21-34
84.
P. Langevitz,N. Kaplinsky,M. Ehrenfeld,M. Pras,R.A Intractable
treatmentwith combined methotrexate, azathioprine and hydroxychloroquine
Br J Rheumatol, 28 (1989), pp. 271-272
85.
D.L. Scott,P.T. Dawes,E. Tunn,P.D. Fowler,M.F. Shandforth,J. Fisher
Combination therapy with gold and hydroxychloroquine in rheumatoidarthritis: a prospective, randomized, placebo-controlled study
Br J Rheumatol, 28 (1989), pp. 128-133
86.
D.R. Porter,H.A. Capell,J. Hunter
Combination therapy in rheumatoidarthritis–no benefit of addition of hydroxychloroquine to patients with asuboptimal response to intramuscular gold therapy
J Rheumatol, 20 (1993), pp. 645-649
87.
M. Martin
A combination of D-penicillamine and hydroxychloroquine for the treatment of rheumatoid arthritis
Ann Rheum Dis, 41 (1982), pp. 208
88.
T.W. Bunch,J.D. O’Duffy,R.B. Tompkin,W.M. O’Fallon
Controlled trial of hydroxychloroquine and D-penicillamine singly and in combination in the treatment of rheumatoid arthritis
Arthritis Rheum, 27 (1984), pp. 267-276
89.
T. Gibson,P. Emery,R.D. Armstrong,A.J. Crisp,G.S. Panayi
Combined D-penicillamine and chloroquine treatment of rheumatoid arthritis-a comparative study
Br J Rheumatol, 26 (1987), pp. 279-284
90.
K.L. Faarvang,C. Egsmose,P. Kryger,J. Podenphant,M. Ingeman-Nielsen,T.M. Hansen
Hydroxychloroquine and sulphasalazine alone and in combination in rheumatoid arthritis: a randomised double blind trial
Rheum Dis, 52 (1993), pp. 711-715
91.
J.F. Fries,G. Singh,L. Lenert,D.E. Furst
Aspirin, hydroxychloroquine, and hepatic enzyme abnormalities with methotrexate in rheumatoid arthritis
Arthritis Rheum, 33 (1990), pp. 1611-1619
92.
P. Seideman,F. Albertioni,O. Beck,S. Eksborg,C. Peterson
Chloroquinereduces the bioavailability of methotrexate in patients with rheumatoidarthritis. A possible mechanism of reduced hepatotoxicity
Arthritis Rheum, 37 (1994), pp. 830-833
93.
J.R. O’Dell,C.E. Haire,N. Erikson,W. Drymalski,W. Palmer,S. Eckiioff
Treatment of rheumatoid arthritis with methotrexate alone, sulfasalazine and hydroxychloroquine, or a combination of all three medications.?
Engl J Med, 334 (1996), pp. 1287-1291
94.
T. Mottonen,P. Hannonen,M. Leirisalo-Repo,M. Nissila,H. Kautiainen,M. Korpela
Comparison of combination therapy with single-drugtherapy in early rheumatoid arthritis: a randomised trial. FIN-RACo trial group
Lancet, 353 (1999), pp. 1568-1573
95.
M. Calguneri,S. Pay,Z. Caliskaner,S. Apras,Kiraz,I. Ertenli
Combination therapy versus monotherapy for the treatment of patients with rheumatoid arthritis
Clin Exp Rheumatol, 17 (1999), pp. 699-704
96.
K. Puolakka,H. Kautiainen,T. Mottonen,P. Hannonen,M. Korpela,H. Julkunen
Impact of initial aggressive drug treatment with a combinationof disease-modifying antirheumatic drugs on the development of work disability in early rheumatoid arthritis: a five-year randomized followup trial
Arthritis Rheum, 50 (2004), pp. 55-62 http://dx.doi.org/10.1002/art.11436
97.
D.J. Wallace
The use of chloroquine and hydroxychloroquine for non-infectious conditions other than rheumatoid arthritis or lupus: a critical review
Lupus, 5 (1996), pp. S59-S64
98.
R.I. Fox,E. Chan,L. Benton,M. Friedlaender,F.V. Howell
Treatment of primary Sjogren’s syndrome with hydroxychloroquine
Am J Med, 85 (1988), pp. 62-67
99.
R.I. Fox,R. Dixon,V. Guarrasi,S. Krubel
Treatment of primary Sjögren’ssyndrome with hydroxychloroquine: a retrospective, open-label study
Lupus, 5 (1996), pp. S31-S36
100.
A.A. Kruize,R.J. Hene,C.G. Kallenberg,O.P. Bijsterveld,A. Van der Heide,L. Kater
Hydroxychloroquine treatment for primary Sjögren’s syndrome: a two year double blind crossover trial
Ann Rheum Dis, 52 (1993), pp. 360-364
101.
L. González-López,J.I. Gámez-Nava,G. Jhangri,A.S. Russell,M.E. Suárez-Almazor
Decreased progression to rheumatoid arthritis or other connective tissue diseases in patients with palindromic rheumatism treated with antimalarials
J Rheumatol, 27 (2000), pp. 41-46
102.
W. Youssef,A. Yan,A.S. Russell
Palindromic rheumatism: a response tochloroquine
J Rheumtol, 18 (1999), pp. 35-37
103.
D.D. Gladman,R. Blake,B. Brubacher,V.T. Farewell
Chloroquine therapy in psoriatic arthritis
J Rheumatol, 19 (1992), pp. 1724-1726
104.
B.H. Athreya,J.T. Cassidy
Current status of the medical treatment of children with juvenile rheumatoid arthritis
Rheum Dis Clin North Am, 17 (1991), pp. 871-889
105.
L.R. Bryant,K.F. Des Rosier,M.T. Carpenter
Hydroxychloroquine in the treatment of erosive osteoarthritis
J Rheumatol, 22 (1995), pp. 1527-1531
106.
B. Rothschild,L.E. Yakubov
Prospective 6-month, double-blind trial of hydroxychloroquine treatment of CPDD
Compr Ther, 23 (1997), pp. 327-331
107.
S. Ullberg,N.G. Lindquist,S.E. Sjostrand
Accumulation of chorio-retinotoxic drugs in the foetal eye
Nature, 227 (1970), pp. 1257-1258
108.
C.N. Hart,R.F. Naunton
The ototoxicity of chloroquine phosphate
Arch Otolaryngol Head Neck Surg, 80 (1964), pp. 407-412
109.
P.A. Phillips-Howard,D. Wood
The safety of antimalarial drugs in pregnancy
Safety, 14 (1996), pp. 131-145
110.
N.M. Buchanan,E. Toubi,M.A. Khamashta,F. Lima,S. Kerslake,G.R. Hughes
Hydroxychloroquine and lupus pregnancy: review of a series of 36 cases
Ann Rheum Dis, 55 (1996), pp. 486-488
111.
A.L. Parke,B. West
Hydroxychloroquine in pregnant patients with SLE
Rheumatol, 23 (1996), pp. 1715-1718
112.
P. Goupille
Grossesse et polyarthrite rhumatoïde
Rev Rhum. (Suppl Pédagogique), 64 (1997), pp. 174SP-182SP
113.
G. Klinger,Y. Morad,C.A. Westall,C. Laskin,K.A. Spitzer,G., etal Koren
Ocular toxicity and antenatal exposure to chloroquine or hydroxychloroquine for rheumatic diseases
114.
R.A. Levy,V.S. Vilela,M.J. Cataldo,R.C. Ramos,J.L. Duarte,B.R. Tura
Hydroxychloroquine (HCQ) in lupus pregnancy: double-blind and placebo-controlled study
Lupus, 10 (2001), pp. 401-404
115.
N. Costedoat-Chalumeau,Z. Amoura,P. Duhaut,L.T. Huong Du,D. Sebbough,B. Wechsler
Safety of hydroxychloroquine in pregnant patients with connective tissue diseases: a study of one hundred thirty-three cases compared with a control group
Arthritis Rheum, 48 (2003), pp. 3207-3211 http://dx.doi.org/10.1002/art.11304
116.
M. Motta,A. Tincani,D. Faden,E. Zinzini,A. Lojacono,A. Marchesi
Follow-up of infants exposed to hydroxychloroquine given to mothers during pregnancy and lactation
J Perinatol, 25 (2005), pp. 86-89 http://dx.doi.org/10.1038/sj.jp.7211208
117.
A. Al-Herz,M. Schulzer,J.M. Esdaile
Survey of antimalarial use in lupuspregnancy and lactation
J Rheumatol, 29 (2002), pp. 700-706
118.
H.N. Bernstein
Ophthalmologic considerations and testing in patients receiving long-term antimalarial therapy
Am J Med, 75 (1983), pp. 25-34
119.
M.F. Marmor,R.E. Carr,M. Easterbrook,A.A. Farjo,W.F. Mieler
Recommendations on screening for chloroquine and hydroxychloroquine retinopathy
Ophthalmology, 109 (2002), pp. 1377-1382
120.
R. Araiza-Casillas,F. Cárdenas,Y. Morales,M.H. Cardiel
Factors associated with chloroquine-induced retinopathy in rheumatic diseases
Lupus, 13 (2004), pp. 119-124
121.
E.J. Nord,P.K. Shan,R.Z. Rinaldi,M.H. Wisman
Hydroxychloroquine cardiotoxicityin systemic lupus erythematosus: a report of 2 cases and review of the literature
Semin Arthritis Rheum, 33 (2004), pp. 336-351
122.
J.-P. Baguet,F. Tremel,M. Fabre
Chloroquine cardiomyopathy with conductiondisorders
Heart, 81 (1999), pp. 221-223
123.
A. Cervera,G. Espinosa,R. Cervera,J. Font,M. Ingelmo
Cardiac toxicitysecondary to long term treatment with chloroquine
Ann Rheum Dis, 60 (2001), pp. 301
124.
E. Casado,M. Larrosa,J. Gratacós,J.M. Martínez,I. Ojanguren,A. Sanjuán
Antimalarial myopathy: more frecuent than we though? A longitudinal study with 119 patients
Arthritis Rheum, 46 (2002), pp. S612
125.
J.A. Avina-Zubieta,E.S. Johnson,M.E. Suárez-Almanzor,A.S. Russell
Incidenceof myopathy in patients treated with antimalarials. Report of three cases and review of the literature
Br J Rheumatol, 34 (1995), pp. 166-170
126.
D.J. Wallace
Antimalarials-the “real” advance in lupus
Lupus, 10 (2001), pp. 385-387
Correspondencia: Dra. M. Jiménez Palop. Servicio de Reumatología. Hospital Universitario Puerta de Hierro. San Martín de Porres, 4. 28035 Madrid. España. (Mercedes Jiménez Palop mercedes@donpp.com)
Copyright © 2006. Elsevier España S.L. Barcelona
Reumatol Clin 2006;2:190-201 - Vol. 2 Núm.4 DOI: 10.1016/S1699-258X(06)73045-5
Política de cookies
x
Utilizamos cookies propias y de terceros para mejorar nuestros servicios y mostrarle publicidad relacionada con sus preferencias mediante el análisis de sus hábitos de navegación. Si continua navegando, consideramos que acepta su uso. Puede cambiar la configuración u obtener más información aquí.